HA-Tau nanospheres capture inflammatory proteins and restore memory in aged mice

The team from Duke University and UCLA described HA‑Tau — hyaluronic acid conjugated with taurine and formed into nanospheres of about ~200 nanometers — in a preprint dated September 18, 2026 preprint, September 18, 2026. One injection of these nanospheres into old mice after a bone fracture lowered inflammatory proteins in the blood, preserved the blood‑brain barrier, and returned spatial‑memory performance to normal levels.

In 20–22‑month‑old mice (equivalent to elderly humans) the nanospheres administered 30 minutes after a tibial fracture captured roughly ~548 different proteins from plasma, most of them belonging to inflammatory pathways. Levels of IL‑6, IL‑1β and TNF‑α dropped, barrier‑strengthening proteins remained, dye leakage decreased, and glial activation in the hippocampus — the memory centre — nearly returned to baseline, so memory test scores matched those of non‑operated animals.

Molecular docking showed that a partial substitution of taurine for hyaluronic acid — around ~43% — creates new cytokine‑binding sites while strengthening existing ones; full substitution abolishes both effects due to steric hindrance. This optimal degree was chosen by direct testing on blood proteins, where it bound best. Taurine’s controversial reputation in geroscience — highlighted by a Science 2023 article linking low taurine to aging and lifespan extension in mice, though later human data failed to confirm the link — is repurposed here simply as a hook for cytokines.

Tests on plasma from elderly donors and human brain‑vascular cells reproduced the same effect: the nanospheres captured IL‑6, IL‑1β and TNF‑α, which signal through the NF‑κB switch, and made the barrier less permeable than without them. This cytokine node has previously been tied to cognitive impairment in living people by Canadian data.

The nanospheres barely enter the brain and accumulate mainly in the liver, causing no detectable liver damage within the first day; the brain is protected because the substance that intercepts the inflammatory signals never needs to cross the blood‑brain barrier.

🔗 Read original →

Glycocalyx‑edited stem cells reverse osteoporosis in small trial

The approach uses a patient’s own mesenchymal stromal/stem cells (MSCs) harvested from bone marrow, which are bioengineered to restore surface expression of the molecule sLeX. This glyocalyx modification re‑equips the cells with the ability to home to bone marrow after intravenous infusion, turning them into a “living drug”

🔗 Read original →

Naive CD8+ T cells pre‑mark mitochondrial genes with H2A.Z via GABPα and IL‑7 for rapid response

Naive CD8+ T cells mark mitochondrial genes with the histone variant H2A.Z under the direction of GABPα and the background signal IL‑7, allowing them to launch a full effector response within hours of encountering their specific pathogen. This preparatory state weakens with age but can be restored, and the same mechanism enhances anticancer CAR‑T therapy.

The study was conducted by a group from the Chinese Academy of Sciences and published in Science Advances, 18 September. A year earlier the same lab showed that H2A.Z primes memory CD8+ T cells for rapid action; the new work extends this finding to naïve cells that have not yet met a pathogen.

A naive CD8+ T cell is a killer lymphocyte that conserves resources while waiting for its target. Upon recognizing the appropriate threat it has only a few hours to proliferate, produce effector proteins, and remodel its metabolism. How this readiness is kept on pause for years had remained unclear; the answer lies in DNA packaging.

H2A.Z is a histone “spool” around which DNA is wound to fit two meters of genome into a microscopic nucleus. Where H2A.Z resides, chromatin is looser and genes are easier to activate. Mice lacking H2A.Z in T cells show diminished naïve and effector populations, and the remaining cells poorly control a model bacterial infection and melanoma tumor growth.

The defect is specific: without H2A.Z, mitochondrial respiratory‑chain genes activate far less strongly upon stimulation, and adding pure ATP to the culture partially restores activation capacity—indicating that an energy shortage keeps the cells idle.

Mass‑spectrometry identified the depositor of H2A.Z on these genes as GABPα, known since the 1990s as

🔗 Read original →

China adds xenotransplantation, universal cell therapy, and organ growing to 2030 medical industry plan

On September 18 ten Chinese agencies led by the Ministry of Industry and Information Technology released document No. 210 – the medical industry development plan for 2026‑2030. Among its ten targets are industry revenue of 3.5 trillion yuan (~$523 billion) and at least a quarter of global first‑in‑class drugs originating from China.

The plan calls for technological breakthroughs in xenotransplantation (animal‑to‑human organ transplants), universal cell therapy with off‑the‑shelf products, creation of complex regenerable organs, and synthesis of artificial living systems (building functional biological systems from scratch). It also urges expansion of next‑generation genome editing and neuro‑interfaces that link the brain to computers.

Continuing the previous industrial cycle, China launched 230 innovative drugs during 2021‑2025 and ranked second worldwide in drugs under development, per the ministry’s explanation. The plan links this effort to accelerating population aging: by end‑2025 323.38 million people aged 60+ (23 % of the population), according to the National Bureau of Statistics National Bureau of Statistics.

In the traditional Chinese medicine section, anti‑aging agents are listed among new consumer directions alongside elderly care, rehabilitation, and health management. For rare diseases it speeds development of cell and gene therapies – e.g., hemophilia, ALS, and Gaucher disease.

In the first half of 2026 licensing deals for Chinese innovative drugs reached $106.3 billion, versus $135.7 billion for all of 2025. The plan connects these industry scales to concrete technology targets through 2030.

🔗 Read original →

FDA Accepts Reasonable Expectation of Effectiveness Package for Loyal’s LOY-003

On September 16, the FDA accepted an interim submission for Loyal’s LOY-003 that includes a “reasonable expectation of effectiveness” (RXE) determination. This marks the third RXE granted to separate Loyal programs, according to the company. The RXE step evaluates whether a future drug can deliver the claimed benefit.

LOY-003 is a daily tablet designed for large and giant breeds that aims to extend their lifespan. Loyal links the shorter life of these dogs to the hormonal signals GH and IGF-1, which influence body growth. The tablet is intended

🔗 Read original →

Calorie restriction primes mice for fasting hours before the stomach empties

Researchers from Roman Kondratov’s lab at Cleveland State University compared calorie restriction (CR) with a single fast‑feed‑fast cycle (FRF) that delivered the same total amount of food and the same total fasting time. Mice on CR received 70% of their normal ration in one daily meal, ate it within two hours, and then fasted for about 22 hours. The FRF group underwent one 22‑hour fast, a two‑hour feed, then another 22‑hour fast.

In the CR mice, metabolic switches to a fasting mode began many hours before the stomach was empty—insulin fell already after two hours and mTOR activity dropped after six hours, roughly 12 hours before the stomach became empty at around the 18‑hour mark. In the FRF mice, insulin and mTOR changes tracked stomach emptying closely, occurring only after the stomach was nearly empty at about six hours.

The study showed that only CR improved glucose tolerance and kept liver fat low, whereas the FRF mice displayed sharp post‑meal glucose spikes, no improvement in glucose tolerance, and a progressive accumulation of liver fat that peaked around the 18‑hour fasting point.

These results were published 17 September in Cell Reports. The work also builds on earlier findings that functional circadian clocks are required for CR‑mediated lifespan extension, and that the circadian protein PER2 can bind mTOR to tune its response to fasting—a mechanism highlighted in a separate September study.

The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey Hall, Michael Rosbash and Michael Young for elucidating the molecular mechanism of circadian clocks.

🔗 Read original →

TH1834 protects human heart cells from reperfusion injury after heart attack

TH1834 blocking TIP60 protected human heart cells and mini‑tissues grown from stem cells from damage during reperfusion after a heart attack — an effect previously demonstrated only in mice.

Rest

🔗 Read original →

Claude autonomously GPU‑optimizes 36 open‑source biomolecule tools, boosting speed up to 4.1×

On September 17 Anthropic released the Anthropic technical report showing that its research model Claude autonomously optimized code for 36 versions of more than 30 open‑source scientific programs that predict protein 3D shape, design molecules, and analyze genomic data. Two staff members with biology knowledge but no GPU‑coding experience led the effort. Speed and accuracy were validated on thousands of predictions, and all code was made open.

The programs spend most of their compute on triple‑segment comparisons; doubling a molecule’s size raises the cost eight‑fold. Acceleration comes from rewriting low‑level GPU kernels. Claude wrote a set of FlashPairformer kernels that

🔗 Read original →

Platelet protein PF4 links exercise, Klotho, young plasma to rejuvenation and clot risk

A review in Frontiers in Immunology, September 2 synthesizes three 2023 studies showing that exercise, the longevity factor Klotho, and young plasma all raise levels of the platelet protein PF4 in old mice. PF4 then reduces brain inflammation, boosts newborn neurons, and repairs immune cells and bone marrow.

🔗 Read original →

DNA methylation blood study shows most CpG links stable with age, some reconfigured

On 18 September researchers posted a preprint on DNA methylation in whole blood from more than 7500 individuals aged 17 to 99. They focused on CpG sites and defined modules as groups of sites that usually change together.

After removing the average age‑related methylation shift, they built a module network from the youngest group (<36 years) and compared it to seven older groups, isolating changes in connections between sites rather than overall shifts.

The network contained 69 modules; they kept the 53 largest for further analysis. About 70% of these modules showed no significant change in connectivity with age, while 11 modules lost more than 5% of their connectivity from the youngest to the oldest group.

Stable modules tended to lie near gene promoters and in long‑range DNA contacts, whereas changing modules were found in late‑replicating, tightly packed chromatin. The approach builds on work from 2023 that compared similar methylation modules across 348 mammalian species and linked them to biological traits.

🔗 Read original →

CFTR modulator reverses biological aging in cystic fibrosis patients

Eight previously untreated cystic fibrosis patients received elexacaftor/tezacaftor/ivacaftor (ETI) for one year; their median epigenetic age acceleration shifted from +1.92 years to -1.70 years (p=0.008). The findings were reported in a preprint posted September 18, 2024 by researchers at the University of British Columbia.

ETI, marketed as Trikafta/Kaftrio, was approved in 2019 and is suitable for roughly 90% of CF patients; it markedly improves sweat chloride and lung function. In this cohort sweat chloride dropped from 98 to 41 mmol/L and lung function rose from 64.5% to 90% of normal.

Higher epigenetic age acceleration correlated with elevated blood IL‑6, IL‑1β and calprotectin, while DNAmGrimAge2—a clock trained to predict mortality and chronic disease—reflects lung aging. Improved lung function was linked to slower epigenetic aging, whereas higher sweat chloride pointed to faster aging.

An earlier Italian study of 52 adults showed a similar reduction in epigenetic age with ETI; this preprint replicates the observation using a different clock and directly ties the effect to inflammation markers. The synchronized changes in sweat chloride, lung function, inflammation and epigenetic age in the same eight individuals support the hypothesis that epigenetic aging in CF can reverse as rapidly as biochemical markers when CFTR function is restored.

🔗 Read original →

Mathematical control theory reframes aging as loss of safe manageability

The article by Alex Zhavoronkov, founder and CEO of Insilico Medicine, and mathematician Bad Mishra of the Courant Institute at New York University was published in Aging, September 16, 2026.

In their model the body is a point in the space of possible biological states, while drugs and other interventions are forces that push this point in different directions. Biological age is defined as the minimal cost in dose, risk, and time required to return the body to the zone of normal function.

Existing aging theories — López‑Otín’s hallmarks, Aubrey de Grey’s SENS, geroscience, and Blagosklonny’s hyper‑functional theory — describe what changes in cells and tissues with age, but they do not answer the practical question of which intervention, at what dose, and in what sequence to apply to a given organism now.

Six months earlier Zhavoronkov announced that aging clocks are dying and

🔗 Read original →

UK Study Links Neighborhood Deprivation, Crime, and Pollution to Faster Biological Aging

A large British study posted as a preprint on medRxiv on 16 September examined how 30 aspects of the residential environment relate to biological aging in 3307 adults from the UK Understanding Society cohort. The work was led by Gergö Baranyi of University College London and Cathryn Tonne of the Barcelona Institute for Global Health. They used methylation‑based DNA clocks to measure biological age, focusing on white participants only.

Five age‑estimation tests and four analytical methods converged on the same finding: the newest clocks that measure the pace of aging — especially DunedinPACE — showed the strongest links to environmental stressors. Older clocks such as Horvath and Hannum responded weakly, while PhenoAge showed intermediate sensitivity. Notably, the

🔗 Read original →

BCG and Super Human Network Launch First Annual Longevity Industry Review

On

🔗 Read original →

LDDM generative model designs binders for five proteins, with X‑ray confirmation of one predicted pose

A preprint from the EPFL team describing LDDM — a generative model that creates drug‑like molecules fitted to a target protein structure — was released on bioRxiv, September 18. The authors synthesized and tested the model’s proposals for five different proteins, confirming binding in all five cases; for one target the X‑ray pose matched the prediction almost exactly.

LDDM was trained on 836 thousand examples of hidden molecular fragments, a dataset 16 times larger than the entire collection of deciphered protein‑ligand structures in the main global database. By limiting each growth step to chemically purchasable blocks, the model builds synthesizable molecules directly during generation.

In the molecular‑glue experiment linking CDO1 to VHL for degradation, 67% of the LDDM‑designed variants retained nanomolar binding affinity. For a peptide inhibitor of cathepsin S — a cancer‑related enzyme on which the model had never been trained — a single‑amino‑acid substitution improved binding 3.5‑fold, from 70.4 nM to 19.9 nM.

For the metabolic enzyme PGK1 (linked to cancer, Parkinson’s and ALS), the best LDDM molecule bound at 14.7 µM, stronger than the control compound at 30 µM as verified by NMR. LDDM also produced a BRD4 binder with an affinity of 40–60 µM, whose NMR‑observed binding matched the model’s prediction. In the SARS‑CoV‑2 Mac1 challenge, LDDM screened only 57 molecules and identified a chemically distinct hit at 46.2 µM; X‑ray analysis confirmed its pose with an accuracy of 1.4–2.3 Å, whereas a public competition of 23 teams had yielded a best result near 18 µM after testing 1739 compounds.

The model failed to give a clear signal for KRAS, and for Pin1 the crystal pose differed from the prediction. Most hits remain below the potency needed for a drug candidate, which the authors view as a pragmatic compromise enabling experimental testing of designed molecules. Lead author Ilya Igashov — an MIPT graduate and EPFL PhD student under Bruno Correia and Oxford professor Michael Bronstein — notes that LDDM continues the lab’s four‑year trajectory from fragment‑based assembly to de‑novo design and synthesizability prediction.

🔗 Read original →

Bone Healing Model Shows Why Osteoporosis Drugs Lose Effect Over Time

Reviews in Endocrine and Metabolic Disorders published a review on 17 September 2026 from the University of California, Davis lab. The authors describe bone recovery as a coordinated action of hormones, immune cells, and the local stem‑cell niche, and show that aging disrupts this coordination at two distinct, partially reversible levels.

A precise definition of skeletal stem cells emerged in 2018 when a Stanford team isolated and functionally validated such cells in humans using surface markers; that work has been cited over 600 times. Before this, the field relied on the ill‑defined term “mesenchymal stem cells,” a heterogeneous mix lacking reliable links to outcomes.

One of the 2018 discoverers, Thomas Ambrosi, moved to Davis in 2024 and, with co‑author Kun Chen in 2025, demonstrated that human skeletal stem cells exist in at least four states; the state that activates depends on the cell’s anatomical niche and its specific microenvironment.

Bone itself secretes hormones such as osteocalcin and FGF23 that influence brain, kidney, and metabolism. Fracture healing proceeds through an active hematoma: neutrophils build a temporary matrix within 48 hours, then macrophages pass through four states from inflammatory to reparative. Administering mice the CSF1R blocker pexidartinib from days 3 to 14 after fracture reduces macrophage accumulation, lessens scarring, and accelerates union.

Aging affects the system on two levels. Young blood rejuvenates many tissues—parabiosis of old and young mice extends old‑mouse lifespan by 10%—but does not restore skeletal stem‑cell function; Ambrosi’s earlier work showed these cells lose bone‑forming capacity and are not rescued by young‑blood infusion or hematopoietic transplant. In contrast, the niche defect is reversible: declining tenascin C with age impairs macrophage recruitment to injury, and restoring this protein in mice renews old animals’ bone‑healing ability.

Osteoporosis afflicts one third of women and one fifth of men over 50 according to the International Osteoporosis Foundation, leading to as many as up to 37 million fractures per year. Estrogen deficiency directly harms skeletal stem cells, while glucocorticoids disrupt bone‑vascular coupling via the protein basigin; blocking basigin with an antibody prevents bone loss in mice (demonstrated by

🔗 Read original →

Diffusion model converts MRI to PET-like brain map, boosting dementia diagnosis accuracy

On September 17,

🔗 Read original →

Cholesterol Switch Controls Lysosomal Mitochondrial Cleanup

Scientists identified a cholesterol‑dependent switch that determines whether lysosomes can fully digest damaged mitochondria. The finding was reported Nature Communications, 16 September by the laboratory of Yasuori Saheki at Nanyang Technological University, Singapore.

The lysosome normally contains little cholesterol; the enzyme PI4KIIα marks its membrane with a lipid tag that recruits the transporter OSBP to pump cholesterol from the endoplasmic reticulum. This influx is required to maintain lysosomal acidity, membrane integrity, and to complete the digestion process.

The cholesterol supplied comes from the ER, not from the damaged mitochondrion itself, and its transport activates SREBP-2, which synthesizes new cholesterol to replenish both the lysosome and ER stores. Earlier work from the same lab showed that OSBP hyperactivation lowers ER cholesterol and triggers SREBP-2 activation.

When cells were deprived of cholesterol, lysosomes digested damaged mitochondria poorly, lost acidity, and their membranes became more fragile; restoring cholesterol rescued all three defects, demonstrating that cholesterol influx is essential for complete digestion.

Free fatty acids released from the broken mitochondria are converted by DGAT1 into neutral fat and stored in lipid droplets, preventing cytoplasmic toxicity; this pathway is activated specifically during mitochondrial damage (e.g., iron depletion) but not during general starvation.

The authors link the mechanism to neurodegeneration, noting that mutations in PINK1 and Parkin cause hereditary Parkinson’s disease, and lysosomal dysfunction is observed in Alzheimer’s where lysosomal pathway risk scores match brain damage; the connection is drawn from independent literature on lysosomal defects in these diseases.

Each component of the pathway — PI4KIIα, OSBP, and SREBP-2 — was sequentially inhibited and then cholesterol was re‑added; the digestive defect was rescued each time, confirming a causal role for every step. Experiments were performed in skin cell cultures and other cell lines.

🔗 Read original →

AI Agent Evaluates Severity of All Human Genetic Disease Traits

An autonomous AI agent built on GPT‑4o independently assessed the severity of all 10,211 Human Phenotype Ontology terms by scanning PubMed and applying ACMG criteria, with the work released as a preprint on Sep 17, 2025 preprint, Sep 17, 2025. The agent aggregated these evaluations to the level of 8,738 gene‑disease pairs.

To ensure verifiability, the team used a ReAct framework: the agent must cite a source for every conclusion and cannot rely on internal model knowledge. After testing six models, including GPT‑5 and Grok‑4, they selected GPT‑4o for its 92% accuracy and balanced reasoning. A separate controller agent weights evidence and forwarded 1,161 low‑confidence assessments to human reviewers.

On a set of 941 phenotypes independently labeled by two geneticists, the agent agreed in 93.55% of cases. At the gene‑disease level, it classified 79.5% of the 8,738 pairs as severe or very severe. The resulting severe‑gene list matched the Australian Mackenzie’s Mission carrier‑screening panel at 95.2% and the ACMG carrier panel at 99.3% New England Journal of Medicine, 2024.

Processing one trait costs about 10 cents, so the full set of 10,211 terms required roughly $1,000—a fraction of the years needed by expert committees. The agent reproduced independent severity judgments for 29 genes in 20 cases, assigned a stricter category in eight, and under‑rated only one gene (BCKDHB). About a third of terms (e.g., headache) could not be placed on the severity scale. Rights to the technology belong to UNSW Sydney and are partially licensed to 23Strands.

🔗 Read original →

AlphaGenome and AlphaMissense assess somatic mutation impact across 8800 tumors

On 16 September, the Ilias Georgakopoulos‑Soares lab at the University of Texas at Austin posted a preprint on medRxiv evaluating AlphaGenome and AlphaMissense. The models were applied to 8800 patients with 33 cancer types from The Cancer Genome Atlas (TCGA) to measure gene damage from somatic mutations. In patients lacking known “hotspot” driver mutations, this damage correlated with survival and treatment outcome in an independent cohort of 570 tumors.

Oncogenomics

🔗 Read original →

Peptide C43-4 Activates APC/C-Cdh1 to Extend Lifespan in Yeast and Worms

The peptide C43-4 was identified as the first activator of the APC/C-Cdh1 complex, a molecular machine that tags unnecessary proteins for destruction and thereby keeps cells in a healthy quiescent state. In yeast and C. elegans, C43-4 extended lifespan through a conserved longevity pathway involving the daf-16 (FOXO relative) and aak-2 (AMPK relative) genes.

APC functions by marking excess proteins for degradation; when paired with Cdc20 it drives cell division, whereas with Cdh1 it maintains a non‑dividing but viable quiescent state. The Cdh1 form deteriorates with age, causing APC substrates to accumulate—a change regarded as a molecular hallmark of aging, which the authors demonstrated in aging yeast cells.

Results were published 16 September in the journal Genetics. Chemical activators of the APC/Cdc20 branch are already tested as anticancer agents (without success); they prolonged the life of dividing yeast but not quiescent cells, which require a Cdh1‑specific activator.

The peptide library that yielded C43-4 originated from earlier work on reversing breast‑cancer drug resistance, where C43-4 also inhibited tumor growth in mice. Only C43-4 prolonged yeast lifespan in quiescence, and it did so exclusively via Cdh1. C43-4 contains a D‑box motif RxxL, the same signal used by natural APC substrates for recognition by Apc10.

Mutational analysis revealed that a single amino acid, D7 (located outside the D‑box), is essential; without D7 the peptide fails to bind Apc10 and loses its lifespan‑extending activity, indicating precise target recognition rather than nonspecific effects.

Synthetic

🔗 Read original →